With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

With pharmaceutical GLP-1 drugs like semaglutide in high demand, Metamorphx offers a plant-based alternative designed to ...

Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...

It’s a condition that’s been around as long as humans have been hirsute, but thinning hair has been making headlines over the past year, thanks to the global increase in the use of GLP-1 weight loss ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

The United States Food and Drug Administration (FDA) has stopped the sale of copycat versions of Ozempic and Wegovy, the Type 2 diabetes drugs used for weight loss. In 2022, the FDA announced ...

The molecule is semaglutide, and it's sold under the name Ozempic for type 2 diabetes and Wegovy for weight ... They are large molecule drugs, so complex in structure and must be administered by ...

Pfizer has decided to discontinue development of the molecule,” Pfizer said in a statement. That was music to the ears of investors in Novo Nordisk, which makes diabetes and obesity treatments Ozempic ...

Sign up for the best picks from our travel, fashion and lifestyle writers. But alongside the well-documented weight-loss effects, emerging scientific research has ...

Blue Cross Blue Shield of Massachusetts says it will soon stop covering popular drugs for weight loss, like Ozempic and Wegovy. The medications have skyrocketed in price and popularity ...

many current molecular property prediction models are based on 2D molecular graphs, neglecting the 3D characteristics of molecules. Therefore, in this paper, we propose the structure-based robust ...